Key Points
- Natera insider Solomon Moshkevich sold 3,000 shares on June 1 at an average price of $218.43, for total proceeds of $655,290. The sale was made under a pre-arranged Rule 10b5-1 plan.
- Following the transaction, Moshkevich still owned 137,643 shares valued at about $30.1 million, representing a 2.13% decrease in his position. He has also made several other Natera stock sales in recent months.
- Natera shares were down 0.4% and opened at $211.85, while analysts remain broadly positive with a Moderate Buy consensus and an average price target of $256.81.
Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 3,000 shares of the company's stock in a transaction on Monday, June 1st. The stock was sold at an average price of $218.43, for a total transaction of $655,290.00. Following the sale, the insider directly owned 137,643 shares of the company's stock, valued at $30,065,360.49. The trade was a 2.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Solomon Moshkevich also recently made the following trade(s):
- On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The stock was sold at an average price of $202.84, for a total transaction of $335,091.68.
- On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The stock was sold at an average price of $203.69, for a total transaction of $693,564.45.
- On Monday, April 27th, Solomon Moshkevich sold 2,182 shares of Natera stock. The stock was sold at an average price of $204.10, for a total transaction of $445,346.20.
- On Wednesday, April 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $202.30, for a total transaction of $606,900.00.
- On Tuesday, March 10th, Solomon Moshkevich sold 915 shares of Natera stock. The stock was sold at an average price of $204.13, for a total transaction of $186,778.95.
Natera Stock Down 0.4%
Natera stock opened at $211.85 on Thursday. Natera, Inc. has a 52-week low of $131.81 and a 52-week high of $256.36. The firm has a market capitalization of $30.34 billion, a price-to-earnings ratio of -129.97 and a beta of 1.56. The company has a fifty day simple moving average of $203.28 and a 200-day simple moving average of $215.94.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of NTRA. Coatue Management LLC lifted its position in Natera by 1,446.1% in the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company's stock valued at $603,270,000 after buying an additional 2,463,008 shares during the last quarter. Wellington Management Group LLP lifted its position in Natera by 94.7% in the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company's stock valued at $1,140,026,000 after buying an additional 2,420,263 shares during the last quarter. Norges Bank acquired a new position in Natera in the fourth quarter valued at about $372,398,000. JPMorgan Chase & Co. lifted its position in Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company's stock valued at $2,944,800,000 after buying an additional 1,225,420 shares during the last quarter. Finally, Franklin Resources Inc. lifted its position in Natera by 37.5% in the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company's stock valued at $428,987,000 after buying an additional 727,366 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on the stock. BTIG Research dropped their price objective on shares of Natera from $260.00 to $250.00 and set a "buy" rating for the company in a report on Monday, May 11th. JPMorgan Chase & Co. upped their price objective on shares of Natera from $260.00 to $265.00 and gave the company an "overweight" rating in a report on Friday, May 8th. Wall Street Zen lowered shares of Natera from a "buy" rating to a "hold" rating in a report on Saturday, May 9th. Robert W. Baird set a $265.00 price objective on shares of Natera in a report on Friday, May 8th. Finally, Wolfe Research assumed coverage on shares of Natera in a report on Tuesday. They issued an "outperform" rating and a $260.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $256.81.
Get Our Latest Analysis on Natera
About Natera
(
Get Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
